Results 151 to 160 of about 15,814 (215)

Effects of empagliflozin on right ventricular free-wall strain in patients with heart failure and reduced ejection fraction: results from the Empire HF Trial. [PDF]

ESC Heart Fail
Omar M, Jensen J, Ali M, Frederiksen PH, Kistorp C, Videbæk L, Poulsen MK, Tuxen CD, Borlaug BA, Möller S, Gustafsson F, Køber L, Schou M, Møller JE.   +13 more
europepmc   +1 more source

Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune‐mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital‐based claims database

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1310-1321, August 2026.
In this target trial emulation of patients with immune‐mediated inflammatory diseases and type 2 diabetes, SGLT2 inhibitor initiation was not associated with a clear increase in UTI risk versus metformin, including across immunosuppressive therapy strata.
Hiroshi Tsushima, Nobuyuki Yajima, Takashi Nomiyama, Ryoko Sakai, Hisashi Noma, Akira Katagiri, Naoto Tamura   +6 more
wiley   +1 more source

SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications. [PDF]

Drugs Context
Manunta M, Bruno GM, Ferrantelli A, Ramirez RF, Nardi F.   +4 more
europepmc   +1 more source

Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐PATH study)

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1322-1334, August 2026.
Graphical abstract illustrating the study design, physiological rationale, and key findings of the D‐PATH trial. Dapagliflozin, an SGLT2 inhibitor, lowers HbA1c and body weight while increasing hematocrit and erythropoietin levels. Although an elevated hematocrit could theoretically increase blood viscosity and impair microcirculatory flow, ex vivo ...
Yuki Nakatani, Nobuyuki Banba, Shoya Ono, Tomoki Turumi, Megumi Hoshiai, Takushi Sugiyama, Takashi Tomoe, Hajime Tamiya, Naoyuki Otani, Hiroyuki Sugimura, Hidekazu Ikemiyagi, Yusuke Ohya, Koji Yokokawa, Shinichiro Ueda, Yoshimasa Aso, Yasuhiro Maejima, Takanori Yasu   +16 more
wiley   +1 more source

Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials. [PDF]

EClinicalMedicine
Zeng BY, Hsu CW, Hung CM, Yang WC, Stubbs B, Chen YW, Lei WT, Chen JJ, Chen TY, Hsu SP, Wang HY, Shiue YL, Zeng BS, Li CT, Su KP, Liang CS, Suen MW, Tseng PT.   +17 more
europepmc   +1 more source

Complex Contributions of Methylglyoxal to Pain, Axon Degeneration, and Diabetic Peripheral Neuropathy

Journal of Neurochemistry, Volume 170, Issue 8, August 2026.
This work reviews how the metabolic by‐product methylglyoxal may contribute to the development of diabetic peripheral neuropathy (DPN), a common complication of diabetes characterized by nerve damage and chronic pain in the extremities. In diabetes, methylglyoxal levels rise due to increased glucose metabolism and reduced detoxification capacity. While
Gentry Totta‐Griese, Douglas E. Wright
wiley   +1 more source

Acute vascular redox modulation by SGLT2 inhibition in non-diabetic patients. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Lukenda KC, Gasparovic AC, Milic M, Radovani B, Vuckovic F, Jakab J, Vucic D, Kovacevic A, Gudelj I.   +8 more
europepmc   +1 more source

Hyponatremia correction is associated with increased brain‐derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double‐blind, placebo‐controlled, crossover trial

Journal of Neuroendocrinology, Volume 38, Issue 8, August 2026.
Abstract Chronic hyponatremia is associated with cognitive deficits, yet the underlying mechanisms remain elusive. A cerebral growth factor which is crucial for cognition and memory is brain‐derived neurotrophic factor (BDNF), but its role in hyponatremia has never been investigated.
Eszter Kustos‐Tóth, Julia Beck, Lucia Seeger, Sophie Monnerat, Cemile Bathelt, Julie Refardt, Mirjam Christ‐Crain   +6 more
wiley   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes. [PDF]

Clin Pharmacol Ther
Lin SH, Chen JJ, Hsiao CC, Fang YW, Chen MT, Tsai MH, Yang HY.   +6 more
europepmc   +1 more source

A Systematic Review and Meta‐Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition

Obesity Reviews, Volume 27, Issue 8, August 2026.
ABSTRACT Background In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Amene Saghazadeh, Mahsa Dolatshahi, Soheil Mohammadi, Sara Hosseinzadeh Kassani, Mahshid Naghashzadeh, Joseph E. Ippolito, Claude B. Sirlin, Bettina Mittendorfer, Matthew R. Brier, Suzanne E. Schindler, John C. Morris, Danny Mou, Hani Charles Soudah, Tammie L. S. Benzinger, Cyrus A. Raji   +14 more
wiley   +1 more source